Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 3/20 | 0.51 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.51 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.51 |
| ▸ | BACE1 | P56817 | 8/20 | 0.43 |
| ▸ | CTSD | P07339 | 4/20 | 0.43 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29795087 | 0.94 | PDCD1LG2 (0.49) | ECE1PDCD1LG2CD274BACE1CTSD | |
| SCHEMBL30390448 | 0.92 | CD274 (0.52) | ECE1PDCD1LG2CD274BACE1CTSD | |
| SCHEMBL30390500 | 0.90 | ACE (0.49) | ECE1PDCD1LG2CD274BACE1CTSD | |
| SCHEMBL29531766 | 0.90 | BACE1 (0.46) | ECE1PDCD1LG2CD274BACE1CTSD | |
| SCHEMBL29679836 | 0.90 | PDCD1LG2 (0.48) | ECE1PDCD1LG2CD274BACE1CTSD | |
| SCHEMBL30737622 | 0.90 | ECE1 (0.56) | ECE1PDCD1LG2CD274BACE1CTSD | |
| SCHEMBL29630774 | 0.90 | ECE1 (0.56) | ECE1PDCD1LG2CD274BACE1CTSD | |
| SCHEMBL29630688 | 0.90 | ECE1 (0.52) | ECE1PDCD1LG2CD274BACE1CTSD | |
| SCHEMBL30123154 | 0.89 | CD274 (0.54) | ECE1PDCD1LG2CD274BACE1CTSD | |
| SCHEMBL30123290 | 0.89 | BACE1 (0.50) | ECE1PDCD1LG2CD274BACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117451986-A | Rapid detection test paper for bacillus subtilis plasmin and preparation method thereof | 武汉真福创新生物制药有限公司 | 2024-01-26 | — | — | CN | claimed |
| US-20230414771-A1 | PREPARATION AND USE OF IMMUNOSTIMULATORY CONJUGATED COMPLEXES FOR TARGETED DELIVERY AND ACTIVATION | YAFEI SHANGHAI BIOLOGY MEDICINE SCIENCE & TECHNOLOGY CO., LTD. (CN) | 2023-12-28 | — | — | US | claimed |
| EP-4108675-A1 | PREPARATION AND USE OF IMMUNOSTIMULATORY COUPLING COMPLEX WHICH IS DELIVERED AND ACTIVATED IN TARGETED MANNER | Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. (CN) | 2022-12-28 | — | — | EP | claimed |
| CN-115322258-A | Monoclonal antibody QKMA-1G41 and application thereof | 武汉真福医药股份有限公司 | 2022-11-11 | — | — | CN | claimed |
| US-11319341-B2 | Immune-stimulating soluble doxorubicin-conjugated complex | YAFEI (SHANGHAI) BIOPHARMACEUTICAL CO., LTD. (CN) | 2022-05-03 | — | — | US | claimed |
| CN-113274507-B | Preparation and use of targeted delivery and activation immunostimulatory conjugate complexes | 亚飞（上海）生物医药科技有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-117451986-A | Rapid detection test paper for bacillus subtilis plasmin and preparation method thereof | 武汉真福创新生物制药有限公司 | 2024-01-26 | — | — | CN | disclosed |
| US-20230414771-A1 | PREPARATION AND USE OF IMMUNOSTIMULATORY CONJUGATED COMPLEXES FOR TARGETED DELIVERY AND ACTIVATION | YAFEI SHANGHAI BIOLOGY MEDICINE SCIENCE & TECHNOLOGY CO., LTD. (CN) | 2023-12-28 | — | — | US | disclosed |
| EP-4108675-A1 | PREPARATION AND USE OF IMMUNOSTIMULATORY COUPLING COMPLEX WHICH IS DELIVERED AND ACTIVATED IN TARGETED MANNER | Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. (CN) | 2022-12-28 | — | — | EP | disclosed |
| CN-115322258-A | Monoclonal antibody QKMA-1G41 and application thereof | 武汉真福医药股份有限公司 | 2022-11-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319341-B2 | Immune-stimulating soluble doxorubicin-conjugated complex | TLR3, CD40, TLR6 | ECE1 1561/4885PDCD1LG2 1342/4885CD274 573/4885 |
| US-20230414771-A1 | PREPARATION AND USE OF IMMUNOSTIMULATORY CONJUGATED COMPLEXES FOR TARGETED DELIVERY AND ACTIVATION | CD74, PAICS, MIF | ECE1 3284/4885PDCD1LG2 29/4885CD274 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.